

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10594939
Filing Date	2007-08-02
First Named Inventor	Sugiyama et al.
Art Unit	1635
Examiner Name	Terra C. Gibbs
Attorney Docket Number	14875-0168US1

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS							Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10594939
Filing Date	2007-08-02
First Named Inventor	Sugiyama et al.
Art Unit	1635
Examiner Name	Terra C. Gibbs
Attorney Docket Number	14875-0168US1

1	Ast et al., "Antisense oligonucleotide binding to U5 snRNP induces a conformational change that exposes the conserved loop of U5 snRNA, Nucleic Acids Research, 25(17):3508-3513 (1997)	<input type="checkbox"/>
2	Jin et al., "Polypyrimidine Tract-Binding Protein Down-Regulates Fibroblast Growth Factor Receptor 1 alpha-Exon Inclusion," Cancer Research, 63:6154-6157 (2003)	<input type="checkbox"/>
3	Mallardo et al., "Microtubule-dependent Organization of Vaccinia Virus Core—derived Early mRNAs into Distinct Cytoplasmic Structures," Molecular Biology of the Cell, 12:3875-3891 (2001)	<input type="checkbox"/>
4	Vickers et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents," The Journal of Biological Chemistry, 278(9):7108-7118 (2003)	<input type="checkbox"/>
5	FISH & RICHARDSON P.C., Amendment in Reply to Action dated June 3, 2009 in U.S. App. Ser. No. 10/594,706, filed December 2, 2009, 16 pages	<input type="checkbox"/>
6	U.S. EXAMINER DANA H. SHIN, USPTO Final Office Action in U.S. App. Ser. No. 10/594,706, mailed March 10, 2010, 13 pages	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.